Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: A novel role of α-fetoprotein

Liver International

Volumn 30, Issue 8, 2010, Pages 1161-1168

  Lee, I Cheng ^a,b   Huang, Yi Hsiang ^a,b   Chan, Che Chang ^a,b   Huo, Teh Ia ^a,b   Chu, Chi Jen ^a   Lai, Chiung Ru ^a   Lee, Pui Ching ^a   Su, Chien Wei ^a,b   Hung, Hung Hsu ^a,b   Wu, Jaw Ching ^a,b   Lin, Han Chieh ^a   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

fetoprotein; Chronic hepatitis B; HBeAg negative; Hepatitis B virus; Liver histology

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TAIWAN; TERTIARY HEALTH CARE; TREATMENT INDICATION;

ADULT; AGED; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; BIOPSY; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HISTOLOGICAL TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TAIWAN;

EID: 79951644821     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02301.x     Document Type: Article

References (42)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
3. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29: 100-7.
4. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52-61.
5. Huang YH, Wu JC, Chang TT, et al. Association of core promoter/precore mutations and viral load in e antigennegative chronic hepatitis B patients. J Viral Hepat 2006; 13: 336-42.
6. Lin CC, Wu JC, Chang TT, et al. Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. J Viral Hepat 2001; 8: 438-46.
7. Huang YH, Wu JC, Chang TT, et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigennegative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003; 10: 277-84.
8. Lampertico P, Colombo M. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues. Liver Int 2009; 29: 130-2.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
10. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
11. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virusDNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008; 48: 1451-9.
12. Lai M, Hyatt BJ, Nasser I, CurryM, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-7.
13. Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-84.
14. Tsang PS, Trinh H, Garcia RT, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol 2008; 6: 569-74.
15. El-Zayadi AR, Badran HM, Saied A, et al. Evaluation of liver biopsy in Egyptian HBeAg-negative chronic hepatitis B patients at initial presentation: implications for therapy. Am J Gastroenterol 2009; 104: 906-11.
16. Nguyen MH, Garcia RT, Trinh HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol 2009; 104: 2206-13.
17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
18. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology. 2009; 49: S129-37.
19. Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 1918-22.
20. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
21. Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616-23.
22. Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006; 101: 2537-45.
23. Wang CC, Lim LY, Deubner H, et al. Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT. J Clin Gastroenterol 2008; 42: 820-6.
24. Lok AS, Sterling RK, Everhart JE, et al. Des-gammacarboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
25. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990; 12: 1420-32.
26. Karvountzis GG, Redeker AG. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. Ann Intern Med 1974; 80: 156-60.
27. Bernuau D, Poliard A, Feldmann G. In situ cellular analysis of alpha-fetoprotein gene expression in regenerating rat liver after partial hepatectomy. Hepatology 1988; 8: 997-1005.
28. Silver HK, Gold P, Shuster J, et al. Alpha(1)-fetoprotein in chronic liver disease. N Engl J Med 1974; 291: 506-8.
29. Chen DS, Sung JL. Relationship of hepatitis B surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. Cancer 1979; 44: 984-92.
30. Yang SS, Cheng KS, Lai YC, et al. Decreasing serum alphafetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. J Gastroenterol 2002; 37: 626-32.
31. Males S, Gad RR, Esmat G, et al. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther 2007; 12: 797-803.
32. Chen TM, Huang PT, Tsai MH, et al. Predictors of alphafetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007; 22: 669-75.
33. Yao FY. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J Clin Gastroenterol 2003; 36: 440-2.
34. Luo K, Liu Z, Karayiannis P. Effect of antiviral treatment on alfa-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. J Viral Hepat 2010; DOI: 10.1111/j.1365-2893.2009.01208 [Epub ahead of print].
35. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998; 93: 2452-6.
36. Chu CW, Hwang SJ, Luo JC, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001; 32: 240-4.
37. Hu KQ, Kyulo NL, Lim N, et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; 99: 860-5.
38. Fung J, Lai CL, Fong DY, et al. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 2008; 28: 1408-16.
39. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-45.
40. Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006; 26: 666-72.
41. Shin WG, Park SH, Jang MK, et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008; 40: 267-74.
42. Lee IC, Chan CC, Huang YH, et al. Comparative analysis of non-invasive models to predict early liver fibrosis in hepatitis B e antigen-negative chronic hepatitis B. J Clin Gastroenterol 2010; DOI: 10.1097/MCG.0b013e3181dd5357 [Epub ahead of print].